Sun Pharma introduces STARIZO in India for acute bacterial skin

Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India

Sun Pharmaceutical Industries has launched Tedizolid Phosphate tablets 200 mg in India under the brand name 'STARIZO'. STARIZO (Tedizolid Phosphate) is a novel, oxazolidinone-class antibacterial, used to treat Acute Bacterial Skin and Skin Structure Infection (ABSSSI).

Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India.

“Drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) causing ABSSSIs, are more challenging to treat due to the limited availability of effective treatment options in hospitals. [i] With STARIZO, we are introducing a treatment option which is effective and has the convenience of once-a-day dosing”, said Kirti Ganorkar, CEO - India Business, Sun Pharma.